Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997423 · ClinicalTrials.gov registry record
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
A clinical trial, sponsored by University of Iowa.
- Completed
- Registry status
- 153
- Enrollment target
NCT02997423: Completed study, sponsored by University of Iowa.
NCT02997423 is a clinical trial that has completed, run by University of Iowa. The registered enrollment target is 153 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997423 has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- 153 participants
- Enrollment target
Study Summary
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PFS (secondary outcome) times.
Primary Outcome
This biomarker trial is designed to prospectively evaluate the hypothesis that the overall survival (OS) time of a subject with newly diagnosed primary GBM tumors, treated by standard of care (SOC), is a function of the CcO enzymatic activity in the tumor. OS is defined as the time interval from date of first diagnosis to death from any cause, irrespective of post-SOC therapies, assessed up to 24 months from accrual.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2022-11-30 |
What the finished NCT02997423 record still lists
NCT02997423 is an observational study that tracks outcomes without assigning an intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02997423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02997423 about?
NCT02997423 is a clinical study titled "Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)". This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PF...
What is the current status of trial NCT02997423?
This trial is currently completed. The enrollment target is 153 participants. The study started on 2016-11-30. Estimated completion is 2022-11-30.
Who is sponsoring clinical trial NCT02997423?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI